Compare RVMD & ALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVMD | ALC |
|---|---|---|
| Founded | 2014 | 1945 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Ophthalmic Goods |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.1B | 34.1B |
| IPO Year | 2020 | 2002 |
| Metric | RVMD | ALC |
|---|---|---|
| Price | $190.67 | $65.09 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 12 |
| Target Price | ★ $140.84 | $89.38 |
| AVG Volume (30 Days) | ★ 1.6M | 1.3M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 0.25% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $7.99 |
| Revenue Next Year | $533.02 | $6.38 |
| P/E Ratio | ★ N/A | $38.31 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $42.18 | $61.84 |
| 52 Week High | $224.31 | $87.64 |
| Indicator | RVMD | ALC |
|---|---|---|
| Relative Strength Index (RSI) | 34.73 | 33.06 |
| Support Level | $177.04 | $63.91 |
| Resistance Level | $194.19 | $68.25 |
| Average True Range (ATR) | 7.15 | 1.25 |
| MACD | -2.74 | -0.64 |
| Stochastic Oscillator | 6.27 | 11.25 |
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.